Filtered By:
Drug: Zivast

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 875 results found since Jan 2013.

PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging
Introduction Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin–kexin type 9 and effectively lower low-density lipoprotein cholesterol levels with less side effects than statins. We hypothesise that alirocumab treatment in addition to statin therapy could stabilise intracranial plaque and reduce arterial stenosis. Methods and analysis In this prospective, randomised, open-label, blinded end-point study, we will use h...
Source: BMJ Open - April 29, 2022 Category: General Medicine Authors: Huang, Y.-C., Chang, C.-H., Tsai, Y.-H., Weng, H.-H., Lin, L.-C., Lee, J.-D. Tags: Open access, Neurology Source Type: research

Rutin protects hemorrhagic stroke development via supressing oxidative stress and inflammatory events in a zebrafish model
Eur J Pharmacol. 2022 Apr 22:174973. doi: 10.1016/j.ejphar.2022.174973. Online ahead of print.ABSTRACTIntracerebral haemorrhagic (ICH) stroke is a major cause of death and disability globally, with no proper treatment available so far. Rutin, a dietary flavonoid, has shown protection against cerebral ischemic stroke due to its antioxidant and anti-inflammatory attributes. However, the efficacy of rutin against ICH stroke remained unexplored. Therefore, in the current study, we investigated the effect of rutin in an ICH stroke zebrafish larva model. The larvae were exposed to atorvastatin (1.25 μM) in system water for indu...
Source: European Journal of Pharmacology - April 26, 2022 Category: Drugs & Pharmacology Authors: Anil Kumar Rana Supriya Sharma Shiv Kumar Saini Damanpreet Singh Source Type: research

Statins side effects: Three signs on the skin that could require 'medical attention'
STATINS, such as atorvastatin, are key in reducing life-threatening cholesterol levels for people who are now at heightened risk of a heart attack or stroke.
Source: Daily Express - Health - March 4, 2022 Category: Consumer Health News Source Type: news

Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)
CONCLUSION: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs.PMID:35242328 | PMC:PMC8861410 | DOI:10.1016/j.amsu.2022.103384
Source: Annals of Medicine - March 4, 2022 Category: Internal Medicine Authors: Saeed Kargar Soliemanabad Kimia Rasouli Zakaria Zakariaei Mostafa Soleymani Parastoo Karimi Aliabadi Source Type: research

Low-Density Lipoprotein Cholesterol Level After a Stroke
Randomized clinical trials (RCTs) of statins as the primary prevention for patients with a high serum low-density lipoprotein cholesterol (LDL-C) level and as the secondary prevention after an acute coronary event have shown that lowering serum LDL-C levels reduces the risks of myocardial infarction, stroke, and vascular death. These trials included stroke as a secondary end point but not as an entry criterion. The benefit of LDL-C lowering to reduce the risk of ischemic strokes in primary prevention trials and for patients with coronary heart disease is not necessarily seen among patients who have had a stroke. The Stroke...
Source: JAMA Neurology - February 21, 2022 Category: Neurology Source Type: research

Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction
CONCLUSION: Sodium ozagrel with atorvastatin can reduce inflammatory reactions; regulate ESR and HMGB1, PON-1, and MIF levels; control blood glucose and lipid indexes; and alleviate nerve injury without increasing adverse effects of atorvastatin alone.PMID:35047123 | PMC:PMC8696649 | DOI:10.4239/wjd.v12.i12.2096
Source: Atherosclerosis - January 20, 2022 Category: Cardiology Authors: You Yu Lin Wang Xu Zhu Ya-Fei Liu Hai-Ying Ma Source Type: research

Cerebrovascular Disease and Statins
Front Cardiovasc Med. 2021 Dec 2;8:778740. doi: 10.3389/fcvm.2021.778740. eCollection 2021.ABSTRACTElevated low-density lipoprotein-cholesterol (LDL-C) is a causal factor for the development of atherosclerotic cardiovascular disease (ASCVD); accordingly, LDL-C lowering is associated with a decreased risk of progression of atherosclerotic plaques and development of complications. Currently, statins play a central role in any ASCVD management and prevention strategies, in relation to their lipid-lowering action and potentially to pleiotropic effects. After coronary artery disease, stroke is the most frequent cause of ASCVD m...
Source: Atherosclerosis - December 20, 2021 Category: Cardiology Authors: Luis M Beltr án Romero Antonio J Vallejo-Vaz Ovidio Mu ñiz Grijalvo Source Type: research

Standard-Dose Atorvastatin Treatment in Patients With Symptomatic Middle Cerebral Artery Atherosclerotic Stenosis: A Vessel Wall Magnetic Resonance Imaging Study
Conclusion: Vessel wall magnetic resonance imaging could accurately characterize changes in MCA plaques after lipid-lowering therapy. Standard-dose atorvastatin treatment could stabilize and reverse plaques in northern Chinese patients with SMAS.
Source: Frontiers in Neurology - December 8, 2021 Category: Neurology Source Type: research